Thyrocare Technologies Limited has announced a key leadership appointment with Dr. Ramesh Kinha joining as Chief Operating Officer, effective December 18, 2025. The appointment represents a strategic move to strengthen the company's operational leadership team with an experienced healthcare and diagnostics professional.

Board Approval and Regulatory Compliance

The Board of Directors approved Dr. Kinha's appointment upon recommendation from the Nomination and Remuneration Committee. The decision was formalized through a circular resolution passed on December 18, 2025 at 10:35 A.M. (IST). The appointment has been disclosed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Professional Background and Experience

Dr. Ramesh Kinha brings over 17 years of extensive experience in healthcare and diagnostics across reputed organizations. His most recent role was as Group Director Laboratory Services at Vijaya Diagnostic Centre Limited. Throughout his career, he has held significant leadership positions at several prominent healthcare companies:

• Apollo Health Lifestyle Ltd.
• Medall Healthcare Pvt. Ltd.
• Metropolis Healthcare Limited
• SRL Ltd.

Educational Qualifications and Certifications

Dr. Kinha possesses strong academic credentials and professional certifications that align with his healthcare leadership role:

Core Competencies

Dr. Kinha's expertise spans multiple critical areas essential for operational excellence in the diagnostics industry. His competencies include laboratory services management, operations oversight, quality assurance protocols, and strategic leadership. He also brings valuable experience in cross-functional coordination, customer relationship management, and organization-wide strategic initiatives.

Strategic Impact

The appointment of Dr. Kinha as Chief Operating Officer is expected to enhance Thyrocare Technologies' operational capabilities and strategic execution. His extensive background in laboratory services and diagnostics operations positions him well to contribute to the company's continued growth and operational excellence in the healthcare sector.

Thyrocare Technologies Limited's bonus shares have been pledged by Docon Technologies Private Limited, a subsidiary of API Holdings Limited. This pledge is part of a security arrangement for debentures issued by API Holdings.

Key Details of the Pledge

Background on Thyrocare's Bonus Issue

Thyrocare Technologies had recently announced a bonus issue in the ratio of 2:1, meaning two new bonus equity shares for every one existing equity share held. The details of this corporate action are as follows:

Impact on Shareholding

Despite the increase in the absolute number of shares pledged, the percentage of encumbered shareholding remains unchanged:

Regulatory Compliance

This pledge creation has been disclosed in compliance with Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosure was made to both the National Stock Exchange of India Limited and BSE Limited.

Implications

1. Unchanged Control: The pledge does not alter the overall percentage of shares encumbered, suggesting no change in the effective control or ownership structure of Thyrocare Technologies.

2. Financing for API Holdings: The pledge indicates that API Holdings, the parent company of Docon Technologies, may be using its subsidiary's assets to secure its debt obligations.

3. Transparency: The prompt disclosure of this pledge demonstrates adherence to regulatory requirements and maintains transparency for shareholders and market participants.

Investors and market watchers should note that while the absolute number of shares pledged has increased due to the bonus issue, the relative exposure remains the same. This corporate action does not inherently change the risk profile of the investment but reflects the group's internal financial arrangements.